

# Washington State Immunization Information System Quick Reference Guide



#### Nirsevimab Documentation in the WAIIS

Nirsevimab (Beyfortus) is a long-lasting monoclonal antibody injection for protection against Respiratory Syncytial Virus (RSV). Click here for more information about RSV and Nirsevimab.

Nirsevimab is offered through the Washington State <u>Childhood Vaccine Program</u>. Orders, inventory management, and patient immunization documentation should be completed in the Washington Immunization Information System (WAIIS) for Nirsevimab supplied through the <u>CVP</u>.

Codes and Crosswalks for Fall 2023 RSV vaccines and monoclonal antibody products can be found here.

### **How do I document Nirsevimab injections?**

Nirsevimab injections can be recorded directly into the WAIIS. If your EHR system exchanges data with the WAIIS, you can document Nirsevimab administrations in your EHR to submit the data to the WAIIS.

The WAIIS and most EHR systems are designed to deduplicate records entered for the same patient on the same day. Some patients may receive two injections of Nirsevimab at the same time in different anatomical sites. Starting January 2024, the WAIIS will accept records of two doses of Nirsevimab entered on the same day for the same patient (up to 20 months of age).

ATTENTION: In February 2024, an issue was found in the WAIIS regarding the ability to report two doses of Nirsevimab given to the same patient on the same day. The system cannot currently accept two records of Nirsevimab entered for the same patient on the same day. Our IIS third party vendor is addressing the problem, and a resolution should be implemented soon. We apologize for any inconvenience or confusion.



EHR documentation submitted to the WAIIS via HL7 interface

- Record and submit electronic immunization messages to the WAIIS from your EHR as you do
  for other vaccines. Two doses of Nirsevimab given to the same patient on the same day will
  be accepted by the WAIIS without deduplication for infants up to 20 months old.
- If your EHR system deduplicates two doses of Nirsevimab administered on the same day, you
  will not be able to send both doses electronically and may need to manually enter the
  second dose directly into the WAIIS.

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email doh.information@doh.wa.gov.




# Washington State Immunization Information System Quick Reference Guide



#### Nirsevimab Documentation in the WAIIS

Direct data entry in the WAIIS

• Click <a href="here">here</a> for more about documenting immunization records directly in the WAIIS. You can record a second dose on the same day for the same patient (up to 20 months old).



### How do I manage Nirsevimab inventory in the WAIIS?

Doses of Nirsevimab provided through the Childhood Vaccine Program will be added to your WAIIS inventory when you electronically receive your clinic's order. Click <a href="here">here</a> for more information about ordering and receiving in the WAIIS.

Click <u>here</u> to learn about manually adding products into your clinic's WAIIS inventory, and for guidance on reconciling and reporting inventory.

If you are submitting Nirsevimab immunization records from your EHR to the WAIIS, only one dose will subtract from your clinic's WAIIS inventory if you report a 'double' dose. Report two separate immunization events for two doses to decrement from your WAIIS inventory. Dose volume does not affect inventory quantity in the WAIIS.

<u>Inventory Reconciliation</u> should be completed frequently in the WAIIS to ensure accurate counts. The <u>Lot Usage and Recall Report</u> and the <u>Patient Detail Report</u> are helpful IIS tools to assist with troubleshooting inventory discrepancies.

# What else should I know about documenting Nirsevimab in the WAIIS?

Patient weight data is not supported or accepted by the WAIIS. Because weight information is not recorded, the WAIIS will not detect when an invalid dose is administered.

There is currently no forecasting for Nirsevimab in the WAIIS - refer to current ACIP recommendations.

Click <u>here</u> for guidance on searching for or advertising Nirsevimab available for transfer between healthcare facilities.

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email doh.information@doh.wa.gov.